Scholarlink

<p>No liquid biomarkers are available for monitoring rhabdomyosarcoma, and treatment evaluation is limited to imaging examinations. Circulating tumor DNA (ctDNA) is a promising disease marker in various malignancies, but generalized ctDNA assays targeting recurrent mutations are unsuitable for childhood sarcomas due to genetic heterogeneity. We developed tumor-informed sequencing panels targeting ten single-nucleotide variants per patient and performed ultrasensitive ctDNA analysis of 130 plasma samples in twelve children with rhabdomyosarcoma. Levels of ctDNA correlated with tumor burden, decreased gradually and became undetectable with successful treatment. All four disease relapses and the one case of primary resistant disease were associated with increased ctDNA levels. In one patient, ctDNA was repeatedly positive during five months before clinical relapse. In contrast, all samples collected during follow-up in patients without relapse were ctDNA-negative. Our findings show that ctDNA, analyzed using a tumor-informed approach, is a sensitive and specific biomarker for rhabdomyosarcoma, also for patients lacking recurrent genetic alterations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Patient-specific sequencing panels enable sensitive circulating tumor DNA analysis in rhabdomyosarcoma independent of genetic profile

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月21日

查看全文
  • Ida Rahmqvist,
  • Agnes Dahlstrand Rudin,
  • Elisabeth Mellström,
  • Raghda R. Ibrahim,
  • Daniel Andersson,
  • Fani Pujol Calderón,
  • Anna Ordqvist Redfors,
  • Niki Rostamzadeh,
  • Wilma Franssila,
  • Christin Karlsson,
  • Fanny Zetterlund,
  • Robert Khashan,
  • Hanna Frostdahl,
  • Tobias Österlund,
  • Torben Ek,
  • Henrik Fagman,
  • Anders Ståhlberg,
  • Martin Dalin

摘要

No liquid biomarkers are available for monitoring rhabdomyosarcoma, and treatment evaluation is limited to imaging examinations. Circulating tumor DNA (ctDNA) is a promising disease marker in various malignancies, but generalized ctDNA assays targeting recurrent mutations are unsuitable for childhood sarcomas due to genetic heterogeneity. We developed tumor-informed sequencing panels targeting ten single-nucleotide variants per patient and performed ultrasensitive ctDNA analysis of 130 plasma samples in twelve children with rhabdomyosarcoma. Levels of ctDNA correlated with tumor burden, decreased gradually and became undetectable with successful treatment. All four disease relapses and the one case of primary resistant disease were associated with increased ctDNA levels. In one patient, ctDNA was repeatedly positive during five months before clinical relapse. In contrast, all samples collected during follow-up in patients without relapse were ctDNA-negative. Our findings show that ctDNA, analyzed using a tumor-informed approach, is a sensitive and specific biomarker for rhabdomyosarcoma, also for patients lacking recurrent genetic alterations.